查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1800768

蛋白质体学市场报告（按分析类型、组件类型、技术、应用、最终用户（临床诊断实验室、研究机构等）和地区）2025 年至 2033 年

Proteomics Market Report by Analysis Type, Component Type, Technology, Application, End-User (Clinical Diagnostic Laboratories, Research Organizations, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球蛋白质体学市场规模达415亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到1,394亿美元，2025-2033年期间的复合年增长率（CAGR）为13.68%。目前，北美占据市场主导地位，这得益于其强大的科研基础设施以及製药和生物技术公司的强劲发展。推动该市场发展的因素主要包括质谱技术的快速进步、慢性病发病率的上升以及个人化医疗的快速发展。此外，机器学习（ML）和人工智慧（AI）的日益融合正在升级蛋白质分析和资料解读。

主要部分：

  • 分析类型：根据分析类型，市场细分为结构蛋白质体学、功能蛋白质体学和蛋白质表现蛋白质体学。
  • 组件类型：依组件类型，市场分为核心蛋白质体学服务及生物资讯软体及相关服务。
  • 技术：蛋白质微阵列引领市场，因为它能够快速、大规模地分析蛋白质的相互作用、表现和功能。其高通量特性使其成为生物标记发现和疾病诊断的理想选择。
  • 应用：根据应用，市场分为蛋白质表现谱、蛋白质挖掘和翻译后修饰。
  • 终端用户：药物研发机构占据最大的市场份额，因为他们专注于生物标记识别和疾病机制研究。他们正在大力投资先进的蛋白质体学技术，以加速研发活动。
  • 地区：北美凭藉高额研发投入以及众多生技和製药公司，引领蛋白质体学市场。政府支持、先进的医疗体係以及创新技术的早期应用，进一步巩固了该地区的市场领先地位。

关键参与者：

  • 蛋白质体学市场的领导公司包括安捷伦科技公司、Bio-RAD Laboratories Inc.、布鲁克公司、Creative Proteomics、丹纳赫公司、通用电气医疗集团、堀场製作所、Luminex 公司、默克集团、Perkinelmer 公司、Promega 公司、赛默飞世尔科技公司、沃特世科技公司、沃特世科技公司等。

市场成长的关键驱动力：

  • 个人化医疗需求日益增长：个人化医疗方法促进了蛋白质体学工具在临床和製药领域的广泛应用。蛋白质体学可以识别特定的生物标记物，支持标靶药物开发并改善治疗效果。
  • 癌症研究日益受到关注：蛋白质在肿瘤生物学、进展和抗药性中发挥着至关重要的作用。蛋白质体学分析有助于识别癌症特异性生物标记物，支持早期诊断并指导标靶治疗。这项研究需求正在推动肿瘤学研究领域对蛋白质体学技术的投入。
  • 学术机构与生物技术公司之间的合作：合作伙伴关係正在促进蛋白质体学工具、诊断解决方案和疗法的快速发展。共同努力也能吸引更多资金，扩大研究能力，并加强商业化管道。
  • 单细胞蛋白质体学的兴起：单细胞蛋白质体学的发展使研究人员能够在单一细胞层面上研究蛋白质表现。这项创新揭示了细胞多样性和稀有细胞群，从而增强了对疾病的理解和药物靶向性。
  • 新一代定序 (NGS) 的技术进步：新一代定序的进步正在推动多组学方法的发展。 NGS资料为蛋白质表现研究提供了基因组背景，从而促进了生物标记的发现和精准医疗。

未来展望：

  • 强劲成长前景：由于个人化医疗需求旺盛，以及质谱和生物资讯领域的创新，蛋白质体学市场预计将持续扩张。药物研发和生物标记识别领域的持续研究也为市场扩张提供了进一步的支持。
  • 市场演变：该领域预计将从基础的蛋白质分析转向蛋白质微阵列和生物资讯学工具等先进技术。它在诊断和个人化医疗中发挥着重要作用，反映出生物研究正向更有针对性和基于数据的转变。

蛋白质体学市场因单细胞蛋白质体学的兴起而不断扩张。单细胞蛋白质体学能够深入了解细胞异质性，从而实现更精准的疾病建模和标靶治疗。学术机构与生技公司之间的合作正在加速创新，使研究能够更快地转化为实用的诊断和治疗方案。质谱、蛋白质微阵列和新一代定序（NGS）的技术进步也提高了资料的准确性、通量和成本效益。蛋白质体学仪器的自动化和小型化程度不断提高，提高了效率，减少了样本量，并降低了营运成本。此外，蛋白质体学与基因组学和代谢组学等其他组学平台的整合，使得全面的生物学分析成为可能，进一步拓宽了其应用范围。政府资金投入、对生物标记发现的监管支持，以及蛋白质体学在农业和环境监测领域应用的不断增加，也促进了市场的成长。

蛋白质体学市场趋势：

慢性病和传染病发生率不断上升

慢性病和传染病的高发病率极大地推动了市场的成长。随着癌症、糖尿病、心血管疾病和传染病等疾病的日益普遍，人们越来越需要在分子层面上了解疾病机制。根据美国国立卫生研究院 (NIH) 的数据，预计到 2024 年，美国将新增 2,001,140 例癌症病例。蛋白质体学使研究人员和临床医生能够识别疾病特异性的生物标记、监测病情进展并开发标靶疗法。它还有助于早期诊断，这对于有效管理慢性病至关重要。个人化医疗和精准治疗的需求进一步推动了蛋白质体学工具的使用，因为它们可以更深入地分析蛋白质的相互作用和功能。

增加医药研发活动

日益增长的医药研发活动正在对市场产生正面影响。 《2025 年瑞士生技报告》指出，2024 年瑞士的研发支出达到 26 亿瑞士法郎（31.6 亿美元），私人企业贡献了 14 亿瑞士法郎。随着製药公司加大对药物发现和开发的投入，对能够深入了解蛋白质结构、功能和相互作用的先进工具的需求也日益增长。蛋白质体学使研究人员能够识别和验证潜在的药物标靶，了解疾病途径，并在分子层面评估药物的疗效和毒性。随着标靶疗法的开发，蛋白质体学对于检测疾病特异性生物标记并相应地制定治疗方案变得至关重要。此外，生物製剂和生物相似药的普及进一步加剧了对精确蛋白质分析的需求。

人工智慧应用不断成长

人工智慧的普及简化了资料分析、提高了模式识别能力并加速了生物标记的发现。根据IMARC Group的数据，2024 年全球人工智慧市场规模价值 1,156.2 亿美元。蛋白质体学会产生大量复杂的资料集，需要先进的计算工具才能准确解释。人工智慧演算法（尤其是机器学习）有助于识别与特定疾病相关的细微蛋白质表现模式，从而实现更快、更精确的诊断和药物开发。人工智慧还透过将蛋白质组学资料与其他生物数据集结合，增强了个人化医疗中的预测模型。这种技术协同作用缩短了研究时间，提高了学术和药物研究的效率。此外，面向人工智慧的自动化可最大限度地减少人为错误并降低营运成本。随着各组织将人工智慧整合到其蛋白质体学工作流程中，疾病检测和治疗方面的创新继续快速发展。根据蛋白质体学市场报告，这种技术趋势在塑造产业未来方面发挥着重要作用。

蛋白质体学市场的主要成长动力：

学术机构与生技公司之间的合作

学术机构与生物技术公司之间日益增多的联盟，透过将研究创新与商业落地相结合，显着促进了蛋白质组学市场的成长。学术机构提供深厚的科学知识和前沿发现，而生技公司则提供资源、基础设施和专业知识，将这些发现转化为市场应用。此类合作加速了新型蛋白质体学技术、诊断工具和疗法的开发。合资企业有助于弥合基础研究与实际临床需求之间的差距，从而缩短创新週期。这些合作通常能够吸引公共和私营部门的资金，从而支持大规模蛋白质体学研究和先进的生物标记识别。人才、设备和资料库的共享，进一步增强了研究成果和商业潜力。

单细胞蛋白质体学的出现

单细胞蛋白质体学的出现使研究人员能够在单一细胞层级分析蛋白质，从而深入了解细胞异质性和疾病机制。与对来自众多细胞的讯号进行平均的批量分析不同，单细胞技术可以捕捉每个细胞独特的蛋白质组学谱，从而更深入地了解细胞行为、免疫反应和癌症进展。这种粒度水平对于开发个人化医疗至关重要，因为它有助于识别与疾病相关的稀有细胞类型或亚群。高解析度质谱和微流体平台的日益普及，使得单细胞蛋白质体学更加可行且更具可扩展性。随着研究人员和製药公司越来越多地采用这种方法，它正在为生物标记发现和治疗标靶开闢新的途径。

NGS技术进步

NGS 的技术进步正在增强多组学整合，并拓展生物学洞察的深度。虽然 NGS 主要用于基因组和转录组分析，但其与蛋白质体学的协同作用使我们能够更全面地了解细胞功能。研究人员可以将基因表现资料与蛋白质表现和修饰关联起来，从而改善生物标记识别和疾病建模。单细胞测序和空间转录组学等创新技术正在实现组织内基因和蛋白质网络的高分辨率映射。这些技术使得基于基因组背景设计蛋白质体学实验变得更加容易，从而提高了准确性和相关性。 NGS 的广泛应用也促进了数据驱动的研究策略，推动了对互补蛋白质体学工具的需求。随着 NGS 平台的不断发展，它们将继续支持和拓展蛋白质体学市场的应用。

蛋白质体学市场细分：

按分析类型细分：

  • 结构蛋白质体学
  • 功能蛋白质体学
  • 蛋白质表现蛋白质体学

结构蛋白质体学关注蛋白质相互作用、结构和功能的详细分析。该领域是研究疾病机制和药物开发所必需的。先进的仪器和技术促进了该领域的发展，有助于高解析度结构理解。全球领先的研究机构和公司正在投资结构蛋白质体学，以开发创新的治疗方案。

功能蛋白质体学致力于在生物学背景下识别蛋白质的相互作用和功能。该学科利用先进技术来研究蛋白质修饰、活性和网路的动态变化。在全球蛋白质体学市场中，功能性蛋白质体学在推动个人化医疗、药物研发和疾病诊断领域的创新方面发挥着至关重要的作用。透过洞察蛋白质路径和机制，它促进了标靶治疗和生物标记识别的发展，从而显着提高医疗的有效性和准确性。

蛋白质表现蛋白质体学研究细胞内蛋白质形成的定性和定量方面。它包括高通量技术，用于比较和分析不同治疗或条件下的蛋白质表现量。在全球蛋白质体学市场前景中，该子领域对于理解疾病机制、识别生物标记和创新治疗策略至关重要。能够熟练地监测蛋白质表现在多种刺激下的变化，有助于开发更有效率、更个人化的医疗方案，并实现疾病的早期检测。

按组件类型细分：

  • 核心蛋白质体学服务
  • 生物资讯软体及相关服务

核心蛋白质体学服务包括利用色谱和质谱等先进技术进行蛋白质鑑定、定量和分析。这些服务使研究人员能够解析复杂的蛋白质相互作用和功能，从而简化治疗标靶、疾病机制和生物标记识别的探索。专业的资料采集、解析和样品製备对于获得准确的结果至关重要。

生物资讯软体及相关服务为资料视觉化和分析提供了关键工具。这些服务包含用于蛋白质结构预测、序列比对和功能註释的演算法。将生物资讯学与蛋白质组学结合，可以将原始资料重新配置为有意义的生物学见解，从而推动研究发展，并促进药物开发和个人化医疗的进步。例如，2023年10月，高清空间蛋白质组学开发商Ionpath推出了用户友好的生物资讯工具MIBIplus和MIBIsight，它们透过使用质谱法研究与免疫肿瘤学相关的各种蛋白质，提供可控的资料解释。

按技术划分：

  • 光谱学
  • 色谱法
  • 电泳
  • 蛋白质微阵列
  • X射线晶体学
  • 表面等离子体共振
  • 其他的

蛋白质微阵列占据主要市场份额

蛋白质微阵列在蛋白质体学市场展现出高通量平台的优势，能够同时分析大量蛋白质样本。透过将蛋白质固定在固体表面，这些阵列能够快速定量和检测，促进全球蛋白质体学市场的治疗开发、生物标记发现和诊断。例如，2024年2月，Infinity Bio公司推出了基于MIPSA技术的新技术，该技术利用蛋白质微阵列方法分析抗体-抗原结合。总部位于马里兰州的PTX Capital和Blackbird BioVentures公司向Infinity Bio公司提供了400万美元的资金用于开发这项技术，该技术能够以高度程式化的方式生产大量蛋白质或胜肽阵列。它还有助于在单一反应中结合全长蛋白质和胜肽，使研究人员能够研究抗体与完整蛋白质三维结构的相互作用，并收集作为抗体表位的特定胜肽序列的资讯。

按应用分类：

  • 蛋白质表现谱
  • 蛋白质体挖掘
  • 翻译后修饰

蛋白质表现谱分析是一项关键技术，能够定量和鑑定特定生物样本中的蛋白质。该技术能够对疾病机制和细胞功能进行有价值的分析，并透过定位与多种疾病相关的特定蛋白质标记物来促进个人化医疗和标靶治疗的发展。

蛋白质体挖掘是一种包容性方法，它涵盖对整个蛋白质组的系统性评估，以发现新的蛋白质并理解其功能。这种方法推动了药物开发和生物标记发现的进步，并有助于深入了解众多疾病的潜在治疗标靶和生物学过程。

翻译后修饰 (PTM) 分析针对蛋白质合成后的化学修饰。这些修饰极大地影响蛋白质的稳定性、功能和相互作用。在全球蛋白质体学市场中，PTM 分析有助于阐明复杂的调控机制，促进创新诊断和治疗方法的发展。

按最终用户分类：

  • 临床诊断实验室
  • 研究机构（药物研发）
  • 其他的

研究机构主导市场

透过利用蛋白质体学资料，研究机构可以发现新的药物标靶，阐明疾病机制，并促进有效治疗方法的开发，从而推动生物技术和製药领域的进步。例如，领先的蛋白质组学公司Olink Holding AB于2024年7月推出了其Olink认证服务提供者网络，该网络将代表全球的服务实验室和合约研究组织（CRO）。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据最大的蛋白质体学市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是最大的区域市场，占据蛋白质体学市场收入的最大份额。

北美市场正在显着成长，主要得益于研发投入的大幅增加以及医疗基础设施的升级。此外，慢性病发病率的上升以及对个人化医疗的日益关注，也推动了市场的成长。此外，政府的大力支持和资金支持也促进了蛋白质体学技术在学术和临床研究中的应用。例如，2023年9月，Multiomics CRO Psomagen在北美为10X Genomics Xenium推出了太空生物学服务。 Psomagen的Xenium服务整合了多种组学平台，包括蛋白质组学、基因组学和转录组学。

（请注意，这只是关键参与者的部分列表，完整列表在报告中提供。）

  • 全球蛋白质体学市场的竞争格局体现在各大公司积极竞争，透过策略合作和技术进步巩固市场地位。例如，2024年4月，Biognosys和Alamar Biosciences宣布建立策略伙伴关係，共同进行基于生物流体的蛋白质体学科学研究。此次合作融合了Biognosys在资料非依赖采集质谱(DIA-MS)方面的专业知识以及Alamar在尖端免疫分析方面的技术优势。目前，市场参与者正致力于研发投入和产品组合的拓展，以引领这个快速发展的产业。为了整合资源和专业知识，收购和合併也很常见。市场目前竞争激烈，对先进诊断工具和精准医疗的需求不断增长，促使企业持续创新。

本报告回答的关键问题

  • 全球蛋白质体学市场有多大
  • 2025-2033年全球蛋白质体学市场的预期成长率是多少
  • 推动全球蛋白质体学市场的关键因素有哪些
  • COVID-19 对全球蛋白质体学市场有何影响
  • 根据技术，全球蛋白质体学市场如何分拆
  • 根据最终用户，全球蛋白质体学市场如何划分？
  • 全球蛋白质体学市场的主要区域有哪些
  • 全球蛋白质体学市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 全球蛋白质体学市场有多大？ 2025-2033年全球蛋白质体学市场的预期成长率是多少？
  • 推动全球蛋白质体学市场发展的关键因素有哪些？
  • COVID-19 对全球蛋白质体学市场有何影响？
  • 根据技术，全球蛋白质体学市场如何分布？
  • 根据最终用户，全球蛋白质体学市场是如何分布的？
  • 全球蛋白质体学市场的关键区域有哪些？
  • 全球蛋白质体学市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球蛋白质体学市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依分析类型

  • 结构蛋白质体学
  • 功能蛋白质体学
  • 蛋白质表现蛋白质体学

第七章：市场区隔：依组件类型

  • 核心蛋白质体学服务
  • 生物资讯软体及相关服务

第八章：市场区隔：依技术

  • 光谱学
  • 色谱法
  • 电泳
  • 蛋白质微阵列
  • X射线晶体学
  • 表面等离子体共振
  • 其他的

第九章：市场区隔：依应用

  • 蛋白质表现谱
  • 蛋白质体挖掘
  • 翻译后修饰

第十章：市场区隔：依最终用户

  • 临床诊断实验室
  • 研究机构（药物研发）
  • 其他的

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Agilent Technologies Inc.
    • Bio-RAD Laboratories Inc.
    • Bruker Corporation
    • Creative Proteomics
    • Danaher Corporation
    • GE Healthcare Inc.
    • Horiba Ltd.
    • Luminex Corporation
    • Merck Group
    • Perkinelmer Inc.
    • Promega Corporation
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: SR112025A2156

The global proteomics market size reached USD 41.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 139.4 Billion by 2033, exhibiting a growth rate (CAGR) of 13.68% during 2025-2033. North America currently dominates the market, driven by its robust research infrastructure and strong presence of pharmaceutical and biotech companies. The market is primarily driven by rapid technological advancements in mass spectrometry, increasing incidents of chronic diseases, and rapid shift towards personalized medicines. Moreover, increasing integration of machine learning (ML) and artificial intelligence (AI) are upgrading protein analysis and data interpretation.

Dominant Segments:

  • Analysis Type: On the basis of analysis type, the market has been segmented into structural proteomics, functional proteomics, and protein expression proteomics.
  • Component Type: Based on component type, the market has been bifurcated into core proteomics services and bioinformatics software and related services.
  • Technology: Protein microarrays lead the market as they enable rapid, large-scale analysis of protein interactions, expressions, and functions. Their high-throughput nature makes them ideal for biomarker discovery and disease diagnostics.
  • Application: On the basis of application, the market has been classified into protein expression profiling, protein mining, and post-translational modifications.
  • End-User: Research organizations (drug discovery) hold the biggest market share because of their focus on biomarker identification and disease mechanism studies. They are heavily investing in advanced proteomic technologies to accelerate research and development (R&D) activities.
  • Region: North America leads the proteomics market due to high R&D investments and a large presence of biotech and pharmaceutical companies. Government support, advanced healthcare systems, and early adoption of innovative technologies are further driving market leadership in the region.

Key Players:

  • The leading companies in proteomics market include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.

Key Drivers of Market Growth:

  • Growing Demand for Personalized Medicine: The personalized approach fosters greater adoption of proteomic tools in clinical and pharmaceutical settings. Proteomics identifies specific biomarkers, supporting targeted drug development and improving therapeutic outcomes.
  • Rising Focus on Cancer Research: Proteins play a crucial role in tumor biology, progression, and drug resistance. Proteomic analysis helps identify cancer-specific biomarkers, supports early diagnosis, and guides targeted therapy. This research demand is enhancing investments in proteomic technologies across oncology studies.
  • Collaborations Between Academic Institutes and Biotech Companies: Partnerships are facilitating faster development of proteomic tools, diagnostic solutions, and therapeutics. Joint efforts also attract more funding, expand research capacity, and strengthen commercialization pipelines.
  • Emergence of Single-Cell Proteomics: The development of single-cell proteomics is allowing researchers to study protein expression at the individual cell level. This innovation reveals cellular diversity and rare populations, enhancing disease understanding and drug targeting.
  • Technological Advancements in Next-Generation Sequencing (NGS): Advancements in next-generation sequencing are enabling multi-omics approaches. NGS data provides genomic context for protein expression studies, improving biomarker discovery and precision medicine.

Future Outlook:

  • Strong Growth Outlook: The proteomics market is expected to see sustained expansion, due to high demand for personalized medicine and innovations in mass spectrometry and bioinformatics. Ongoing research in drug discovery and biomarker identification is further supporting the market expansion.
  • Market Evolution: The sector is anticipated to shift from basic protein analysis to advanced techniques like protein microarrays and bioinformatics tools. It is playing a significant role in diagnostics and personalized medicine, reflecting a shift towards more targeted and data-based biological investigations.

The proteomics market is expanding due to the rise of single-cell proteomics, which offers deep insights into cellular heterogeneity, enabling more accurate disease modeling and therapeutic targeting. Collaborations between academic institutions and biotech companies are accelerating innovations, allowing quicker translation of research into practical diagnostic and therapeutic solutions. Technological advancements in mass spectrometry, protein microarrays, and NGS are also enhancing data accuracy, throughput, and cost-efficiency. Improved automation and miniaturization of proteomics instruments are refining efficiency, reducing sample volumes, and lowering operational costs. Moreover, the integration of proteomics with other omics platforms like genomics and metabolomics is enabling comprehensive biological analysis, further broadening its applications. Government funding, regulatory support for biomarker discovery, and increasing utilization of proteomics in agriculture and environmental monitoring are also contributing to the market growth.

Proteomics Market Trends:

Growing incidence of chronic and infectious diseases

High incidence of chronic and infectious ailments is significantly fueling the growth of the market. As conditions like cancer, diabetes, cardiovascular disorders, and infectious diseases are becoming more widespread, there is a rising need to understand disease mechanisms at the molecular level. As per the NIH, in 2024, it was anticipated that there would be 2,001,140 new cancer cases in the United States. Proteomics enables researchers and clinicians to identify disease-specific biomarkers, monitor disease progression, and develop targeted therapies. It also aids in early diagnosis, which is critical in managing chronic illnesses effectively. The demand for personalized medicine and precision treatment is further promoting the use of proteomics tools, as they allow a deeper analysis of protein interactions and functions.

Increasing pharmaceutical R&D activities

The growing pharmaceutical R&D activities are positively influencing the market. As stated in the Swiss Biotech Report 2025, R&D expenditure in Switzerland amounted to SFr2.6 Billion (USD 3.16 Billion) in 2024, with SFr1.4 Billion contributed by private companies. As pharmaceutical companies are wagering on drug discovery and development, there is a rising demand for advanced tools that can offer insights into protein structures, functions, and interactions. Proteomics enables researchers to identify and validate potential drug targets, understand disease pathways, and assess drug efficacy and toxicity at the molecular level. With a strong focus on developing targeted therapies, proteomics is becoming essential for detecting disease-specific biomarkers and tailoring treatments accordingly. Additionally, the adoption of biologics and biosimilars has further intensified the need for precise protein analysis.

Rising AI adoption

Increasing AI adoption is streamlining data analysis, improving pattern recognition, and accelerating biomarker discovery. As per the IMARC Group, the global AI market size was valued at USD 115.62 Billion in 2024. Proteomics generates massive, complex datasets that require advanced computational tools for accurate interpretation. AI algorithms, particularly ML, help identify subtle protein expression patterns linked to specific diseases, enabling faster and more precise diagnostics and drug development. AI also enhances predictive modeling in personalized medicine by integrating proteomic data with other biological datasets. This technological synergy reduces research timelines and boosts efficiency in both academic and pharmaceutical research. Furthermore, AI-oriented automation minimizes human error and lowers operational costs. As organizations are integrating AI into their proteomics workflows, innovations in disease detection and treatment continue to advance rapidly. According to the proteomics market report, this technological trend plays an important role in shaping the future of the industry.

Key Growth Drivers of Proteomics Market:

Partnerships between academic institutes and biotech companies

Increasing alliances between academic institutes and biotech companies are significantly bolstering the proteomics market growth by combining research innovations with commercial execution. Academic institutions offer deep scientific knowledge and cutting-edge discoveries, while biotech firms provide resources, infrastructure, and expertise to translate these findings into market-ready applications. Such partnerships accelerate the development of novel proteomic technologies, diagnostic tools, and therapeutics. Joint ventures help bridge the gap between basic research and real-world clinical needs, leading to faster innovation cycles. These collaborations often attract funding from both public and private sectors, enabling large-scale proteomic studies and advanced biomarker identification. The shared access to talent, equipment, and databases is further strengthening research output and commercial potential.

Emergence of single-cell proteomics

The emergence of single-cell proteomics is allowing researchers to analyze proteins at an individual cell level, offering insights into cellular heterogeneity and disease mechanisms. Unlike bulk analysis, which averages signals from numerous cells, single-cell techniques capture the unique proteomic profile of each cell, enabling deeper understanding of cell behavior, immune responses, and cancer progression. This level of granularity is crucial for developing personalized medicine, as it helps identify rare cell types or subpopulations involved in disease. The growing utilization of high-resolution mass spectrometry and microfluidic platforms has made single-cell proteomics more feasible and scalable. As researchers and pharmaceutical companies are adopting this approach, it is opening new avenues for biomarker discovery and therapeutic targeting.

Technological advancements in NGS

Technological advancements in NGS are enhancing multi-omics integration and expanding the depth of biological insights. While NGS is primarily used for genomic and transcriptomic analysis, its synergy with proteomics allows a more complete understanding of cellular function. Researchers can correlate gene expression data with protein expression and modifications, leading to improved biomarker identification and disease modeling. Innovations, such as single-cell sequencing and spatial transcriptomics, are enabling high-resolution mapping of gene and protein networks within tissues. These technologies make it easier to design proteomic experiments informed by genomic context, enhancing accuracy and relevance. The widespread availability of NGS also fosters data-driven research strategies, driving the demand for complementary proteomics tools. As NGS platforms are evolving, they continue to support and broaden applications in the proteomics market.

Proteomics Market Segmentation:

Breakup by Analysis Type:

  • Structural Proteomics
  • Functional Proteomics
  • Protein Expression Proteomics

Structural proteomics is concerned with detailed analysis of protein interactions, structures, and functions. This field is required for studying disease mechanism and drug development. Advanced instruments and techniques boost growth, facilitating high-resolution structural comprehensions. Leading research institutions and companies are globally investing in structural proteomics to develop innovative therapeutic solutions.

Functional proteomics emphasizes on recognizing protein interactions and functions within a biological context. This discipline leverages advanced techniques to examine the dynamics of protein modifications, activities, and networks. In the global proteomics market, functional proteomics plays a crucial role by spurring innovations in personalized medicine, drug discovery, and disease diagnostics. By offering discernments into protein pathways and mechanisms, it encourages the development of targeted therapies and biomarker identification, substantially improving the efficacy and accuracy of medical treatments.

Protein expression proteomics examines the qualitative and quantitative aspects of protein formation within cells. It includes high-throughput techniques to compare and profile protein expression levels across various treatments or conditions. In the global proteomics market outlook, this subfield is pivotal for comprehending disease mechanisms, identifying biomarkers, and innovating novel therapeutic strategies. The proficiency of monitoring protein expression changes in response to numerous stimuli facilitates the development of enhanced and effective personalized medical initiatives and early detection of diseases.

Breakup by Component Type:

  • Core Proteomics Services
  • Bioinformatics Software and Related Services

Core proteomics services include the protein identification, quantification, and analysis by leveraging advanced techniques such as chromatography and mass spectrometry. These services permit researchers to interpret complex protein interactions and functions, streamlining discoveries in therapeutic targets, disease mechanisms, and biomarker identification. Specialization in data acquisition, interpretation, and sample preparation is crucial for accurate results.

Bioinformatics software and related services provide crucial tools for data visualization and analysis. These services feature algorithms for protein structural prediction, sequence alignment, and functional annotation. Incorporating bioinformatics with proteomics propels research by reconfiguring raw data into meaningful biological insights, endorsing advancements in drug development and personalized medicine. For instance, in October 2023, Ionpath, a high-definition spatial proteomics developer, launched user-friendly bioinformatics tools named MIBIplus and MIBIsight that offers controlled data interpretation by using mass spectrometry to study various proteins associated with immune-oncology.

Breakup by Technology:

  • Spectroscopy
  • Chromatography
  • Electrophoresis
  • Protein Microarrays
  • X-Ray Crystallography
  • Surface Plasmon Resonance
  • Others

Protein microarrays represent the leading market segment

Protein microarrays demonstrate a high-throughput platform in proteomics market, allowing simultaneous analysis of numerous protein samples. By immobilizing proteins on solid surfaces, these arrays foster rapid quantification and detection, promoting therapeutic development, biomarker discovery and diagnostics within the global proteomics market. For instance, in February 2024, Infinity Bio launched new technology, based on MIPSA technology, that leverages protein microarray method to analyze antibody-antigen binding. Maryland-based PTX Capital and Blackbird BioVentures granted USD 4 million fund to Infinity for the development of this technology, allowing the production of large arrays of proteins or peptides in a highly programmed manner. It also aids in combining full-length proteins and peptides in a single reaction, which allows researchers to study antibodies interaction with the 3D structure of full proteins and collect information on the specific peptide sequences that function as antibody epitopes.

Breakup by Application:

  • Protein Expression Profiling
  • Proteome Mining
  • Post-translational Modifications

Protein expression profiling is a pivotal technique permitting the quantification and identification of proteins within a specific biological sample. This process offers valuable analysis of disease mechanisms and cellular functions, promoting the development of personalized medicine and targeted therapeutics by locating specific protein markers associated with numerous conditions.

Proteome mining is an inclusive approach that encompasses the systematic assessment of the entire proteome to discover novel proteins and apprehend their functions. This method propels advancements in drug development and biomarker discovery, presenting an in-depth understanding of potential therapeutic targets and biological processes for numerous diseases.

Post-translational modification (PTM) analysis targets the chemical modifications post the synthesis of proteins. These modifications greatly influence protein stability, function, and interactions. In the global proteomics market, PTM analysis aids in elucidating complex regulatory mechanisms, promoting the development of innovative diagnostics and treatments.

Breakup by End-User:

  • Clinical Diagnostic Laboratories
  • Research Organizations (Drug Discovery)
  • Others

Research organizations dominate the market

By utilizing proteomic data, research organizations uncover new drug targets, expound disease mechanisms, and boost the development of effective treatments, consequently spurring advancements in biotechnological and pharmaceutical sectors. For instance, in July 2024, Olink Holding AB, a leading proteomics company, launched its network of Olink Certified Service Providers that will represent service labs and contract research organization (CROs) worldwide.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest proteomics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market, holding the largest share of the proteomics market revenue.

The market in North America is undergoing notable growth, principally driven by significant investments in research and development, and upgraded healthcare infrastructure. Furthermore, the increasing incidents of chronic diseases and intensifying focus on personalized medicine is boosting the market growth. In additional, robust support by government and funding initiatives escalate the utilization of proteomics technology in academic and clinical research. For instance, in September 2023, Multiomics CRO Psomagen launched its Spatial Biology services for 10X Genomics Xenium in North America. Psomagen's Xenium Service integrates various omics platforms, including proteomics, genomics, and transcriptomics.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the proteomics industry include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The competitive landscape of the global proteomics market is represented by the presence of major companies that are actively competing to strengthen their market position through strategic collaborations and technological advancements. For instance, in April 2024, Biognosys and Alamar Biosciences announced that they have entered into a strategic partnership for joint scientific research in biofluid-based proteomics. This partnership brings together Biognosys' expertise in data independent acquisition mass spectrometry (DIA-MS) and Alamar's cutting-edge immunoassays. Market players are currently emphasizing on research and development investment and expansion of their product portfolios to lead this swiftly evolving sector. Acquisitions and mergers are also common, aimed at unifying resources and expertise. The market is currently experiencing intense competition, fueled by escalating demand for advanced diagnostic tools and precision medicine, mandating continuous innovation.

Key Questions Answered in This Report

  • 1.How big is the global proteomics market?
  • 2.What is the expected growth rate of the global proteomics market during 2025-2033?
  • 3.What are the key factors driving the global proteomics market?
  • 4.What has been the impact of COVID-19 on the global proteomics market?
  • 5.What is the breakup of the global proteomics market based on the technology?
  • 6.What is the breakup of the global proteomics market based on the end-user?
  • 7.What are the key regions in the global proteomics market?
  • 8.Who are the key players/companies in the global proteomics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Proteomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Analysis Type

  • 6.1 Structural Proteomics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Functional Proteomics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protein Expression Proteomics
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Component Type

  • 7.1 Core Proteomics Services
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bioinformatics Software and Related Services
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Spectroscopy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Chromatography
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Electrophoresis
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Protein Microarrays
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 X-Ray Crystallography
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Surface Plasmon Resonance
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Protein Expression Profiling
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Proteome Mining
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Post-translational Modifications
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Clinical Diagnostic Laboratories
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Research Organizations (Drug Discovery)
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bio-RAD Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bruker Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Creative Proteomics
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Danaher Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 GE Healthcare Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Horiba Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Luminex Corporation
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Perkinelmer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Promega Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Waters Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Proteomics Market: Major Drivers and Challenges
  • Figure 2: Global: Proteomics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Proteomics Market: Breakup by Analysis Type (in %), 2024
  • Figure 4: Global: Proteomics Market: Breakup by Component Type (in %), 2024
  • Figure 5: Global: Proteomics Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Proteomics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Proteomics Market: Breakup by End-User (in %), 2024
  • Figure 8: Global: Proteomics Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Proteomics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 10: Global: Proteomics (Structural Proteomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Proteomics (Structural Proteomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Proteomics (Functional Proteomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Proteomics (Functional Proteomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Proteomics (Protein Expression Proteomics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Proteomics (Protein Expression Proteomics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Proteomics (Core Proteomics Services) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Proteomics (Core Proteomics Services) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Proteomics (Bioinformatics Software and Related Services) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Proteomics (Bioinformatics Software and Related Services) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Proteomics (Spectroscopy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Proteomics (Spectroscopy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Proteomics (Chromatography) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Proteomics (Chromatography) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Proteomics (Electrophoresis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Proteomics (Electrophoresis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Proteomics (Protein Microarrays) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Proteomics (Protein Microarrays) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Proteomics (X-Ray Crystallography) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Proteomics (X-Ray Crystallography) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Proteomics (Surface Plasmon Resonance) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Proteomics (Surface Plasmon Resonance) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Proteomics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Proteomics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Proteomics (Protein Expression Profiling) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Proteomics (Protein Expression Profiling) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Proteomics (Proteome Mining) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Proteomics (Proteome Mining) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Proteomics (Post-translational Modifications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Proteomics (Post-translational Modifications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Proteomics (Clinical Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Proteomics (Clinical Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Proteomics (Research Organizations-Drug Discovery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Proteomics (Research Organizations-Drug Discovery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Proteomics (Other End-Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Proteomics (Other End-Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: North America: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: North America: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: United States: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: United States: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Canada: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Canada: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Asia Pacific: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Asia Pacific: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: China: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: China: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Japan: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Japan: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: India: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: India: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: South Korea: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: South Korea: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Australia: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Australia: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Indonesia: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Indonesia: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Europe: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Europe: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Germany: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Germany: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: France: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: France: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: United Kingdom: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: United Kingdom: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Italy: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Italy: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Spain: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Spain: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Russia: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Russia: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Others: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Latin America: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Latin America: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Brazil: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Brazil: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Mexico: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Mexico: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Others: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Others: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Middle East and Africa: Proteomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Middle East and Africa: Proteomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Proteomics Industry: SWOT Analysis
  • Figure 95: Global: Proteomics Industry: Value Chain Analysis
  • Figure 96: Global: Proteomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Proteomics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Proteomics Market Forecast: Breakup by Analysis Type (in Million USD), 2025-2033
  • Table 3: Global: Proteomics Market Forecast: Breakup by Component Type (in Million USD), 2025-2033
  • Table 4: Global: Proteomics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 5: Global: Proteomics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Proteomics Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 7: Global: Proteomics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Proteomics Market Structure
  • Table 9: Global: Proteomics Market: Key Players